MX2024002970A - Composiciones y metodos para el tratamiento de sinucleinopatias. - Google Patents

Composiciones y metodos para el tratamiento de sinucleinopatias.

Info

Publication number
MX2024002970A
MX2024002970A MX2024002970A MX2024002970A MX2024002970A MX 2024002970 A MX2024002970 A MX 2024002970A MX 2024002970 A MX2024002970 A MX 2024002970A MX 2024002970 A MX2024002970 A MX 2024002970A MX 2024002970 A MX2024002970 A MX 2024002970A
Authority
MX
Mexico
Prior art keywords
methods
compositions
synucleinopathies
treating synucleinopathies
synucleinopathy
Prior art date
Application number
MX2024002970A
Other languages
English (en)
Spanish (es)
Inventor
John Smith
Mark Cornell Manning
Pekka Kallunki
Derrick Spencer Katayama
Frank Larsen
Søderberg Josefine Nielsen
Louise Buur
Henrik Rajesh Kumar Parshad
Anne Sofie Markussen
Magdalena Gauden
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MX2024002970A publication Critical patent/MX2024002970A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
MX2024002970A 2021-09-16 2022-09-13 Composiciones y metodos para el tratamiento de sinucleinopatias. MX2024002970A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP21197120 2021-09-16
PCT/EP2022/075402 WO2023041524A2 (en) 2021-09-16 2022-09-13 Compositions and methods for treating synucleinopathies

Publications (1)

Publication Number Publication Date
MX2024002970A true MX2024002970A (es) 2024-03-27

Family

ID=78049153

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024002970A MX2024002970A (es) 2021-09-16 2022-09-13 Composiciones y metodos para el tratamiento de sinucleinopatias.

Country Status (12)

Country Link
US (6) US12077578B2 (cg-RX-API-DMAC7.html)
EP (1) EP4401770A2 (cg-RX-API-DMAC7.html)
JP (1) JP2024534947A (cg-RX-API-DMAC7.html)
KR (1) KR20240055758A (cg-RX-API-DMAC7.html)
CN (1) CN117915952A (cg-RX-API-DMAC7.html)
AR (1) AR127054A1 (cg-RX-API-DMAC7.html)
AU (1) AU2022348798A1 (cg-RX-API-DMAC7.html)
CA (1) CA3230055A1 (cg-RX-API-DMAC7.html)
CL (2) CL2024000753A1 (cg-RX-API-DMAC7.html)
IL (1) IL311344A (cg-RX-API-DMAC7.html)
MX (1) MX2024002970A (cg-RX-API-DMAC7.html)
WO (1) WO2023041524A2 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies
IL326387A (en) * 2023-09-14 2026-04-01 Hoffmann La Roche Antibody formulation
WO2025186235A1 (en) 2024-03-05 2025-09-12 H. Lundbeck A/S Compositions and methods for treating multiple system atrophy (msa)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2361928T3 (en) * 2003-05-19 2017-07-03 Prothena Biosciences Ltd Truncated fragments of alpha synuclein in Lewy body disease
US10513555B2 (en) * 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
WO2017176835A2 (en) * 2016-04-06 2017-10-12 Imago Pharmaceuticals, Inc. Therapeutic antibodies for treatment of neurodegeneration
RU2019114679A (ru) * 2016-11-15 2020-12-17 Х. Лундбекк А/С Средства, пути применения и способы лечения синуклеопатии
JOP20190227A1 (ar) * 2017-03-31 2019-09-30 Biogen Int Neuroscience Gmbh تركيبات وطرق لعلاج اعتلالات السينوكلين
IL311344A (en) 2021-09-16 2024-05-01 H Lundbeck As Preparations and methods for the treatment of synoclinopathies

Also Published As

Publication number Publication date
WO2023041524A3 (en) 2023-05-11
US12351624B2 (en) 2025-07-08
US12358975B2 (en) 2025-07-15
JP2024534947A (ja) 2024-09-26
US20240400661A1 (en) 2024-12-05
EP4401770A2 (en) 2024-07-24
CA3230055A1 (en) 2023-03-23
CL2024003713A1 (es) 2025-04-21
IL311344A (en) 2024-05-01
CN117915952A (zh) 2024-04-19
US20240400660A1 (en) 2024-12-05
AU2022348798A1 (en) 2024-03-14
US20240400662A1 (en) 2024-12-05
US12358974B2 (en) 2025-07-15
CL2024000753A1 (es) 2024-09-23
US20240025979A1 (en) 2024-01-25
US20250084156A1 (en) 2025-03-13
WO2023041524A2 (en) 2023-03-23
KR20240055758A (ko) 2024-04-29
US12077578B2 (en) 2024-09-03
US20260217807A1 (en) 2026-07-30
AR127054A1 (es) 2023-12-13

Similar Documents

Publication Publication Date Title
WO2023041524A3 (en) Compositions and methods for treating synucleinopathies
MX385543B (es) Uso de un anticuerpo biespecífico para tratar cáncer de linfocitos b.
MX2020010603A (es) Extracto de cáñamo para tratamiento de dolor en animales.
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
MY168791A (en) Carbamate compounds and of making and using same
EA201890009A1 (ru) Ингибиторы ezh2 для лечения лимфомы
GEP20146198B (en) Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
MX383866B (es) Inhibidores de ezh2 para tratar linfomas.
BR112015009559A2 (pt) uso de composto antissenso na preparação de medicamento para tratamento de cãncer, composto antissenso e composição farmacêutica
EA201792623A1 (ru) Композиции, содержащие ингибитор стволовости рака и иммунотерапевтический агент, для применения в лечении рака
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
EA201101192A1 (ru) Фармацевтическая композиция, включающая производные глюкопиранозилдифенилметана, фармацевтическая дозированная форма, содержащая указанные производные, способ их получения и применения для улучшения гликемического контроля у пациентов
BR112019017393A8 (pt) Composição farmacêutica de evolocumab e seu uso, kit, método para preparar polipeptídeo de ligação a pcsk9 e método para formular polipeptídeo terapêutico
SG10201902664RA (en) Combination therapy for treating cancer
FR3034993B1 (fr) Conditionnement unitaire, compositions et schemas therapeutiques pour l'administration de stimulateurs des voies de pro-resolution sur des surfaces keratiniques
MX2019008999A (es) Composicion inyectable para prevenir la perdida del pelo o estimular el crecimiento del pelo.
RU2013132566A (ru) Терапевтическое средство от грыжи межпозвоночного диска
BR112017007708A2 (pt) composto macrocíclicos, uso de um composto macrocíclicos, método para tratamento, unidade de dose, composição farmacêutica e método para tratar câncer em um paciente
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
MY181928A (en) Sodium channel modulators for the treatment of pain and diabetes
PH12020500666A1 (en) Pladienolide compounds and their use
UA50333U (ru) Средство от перхоти для укрепления и улучшения качества волос
CR20220586A (es) Moléculas de fijación para el tratamiento de cáncer
EA201270784A1 (ru) Монотерапевтические композиции селективного липофильного и бета-агониста длительного действия и способы косметического лечения ожирения и контурного выпячивания
MX2018004296A (es) Combinacion de un agonista selectivo de il-2rbeta y un agonista il-15 de accion prolongada.